search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


'PRIAS: Prostate cancer Research International: Active Surveillance - guideline and study for the expectant management of localized prostate cancer with curative intent'.


- candidate number5440
- NTR NumberNTR1718
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR11-mrt-2009
- Secondary IDs2004-339 MEC ErasmusMC
- Public Title'PRIAS: Prostate cancer Research International: Active Surveillance - guideline and study for the expectant management of localized prostate cancer with curative intent'.
- Scientific Title'PRIAS: Prostate cancer Research International: Active Surveillance - guideline and study for the expectant management of localized prostate cancer with curative intent'.
- ACRONYMPRIAS
- hypothesisEarly prostate cancer may safely be managed with an active surveillance strategy, avoiding overtreatment and the risk of resulting side effects.
- Healt Condition(s) or Problem(s) studiedProstate cancer
- Inclusion criteria1. Provene adenomcarcinoma of the prostate;
2. CLinical stage T1C/T2;
3. Prostate specific antigen =<10.0 ng/ml;
4. PSA density <0.2;
5. 1-2 positive prostate biopsies;
6. Gleason score 3+3=6 or more favorable.
- Exclusion criteriaDuring follow-up:
1. PSA doubling time <3 years;
2. Clinical stage >T2;
3. >2 positive prostate biopsies;
4. Gleason score >3+3=6.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-dec-2006
- planned closingdate1-dec-2021
- Target number of participants2000
- InterventionsNone, observational study.
- Primary outcomeTreatment free survival.
- Secondary outcomeProstate cancer specific and overall mortality.
- TimepointsYearly analyses are being performed.
- Trial web sitewww.prias-project.org
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD Roderick Bergh, van den
- CONTACT for SCIENTIFIC QUERIESMD Roderick Bergh, van den
- Sponsor/Initiator Erasmus Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Prostate Cancer Research Foundation (SWOP) Rotterdam, The Netherlands
- PublicationsProspective validation of active surveillance in prostate cancer: the PRIAS study.
van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH.
Eur Urol. 2007 Dec;52(6):1560-3. PMID: 17532115.

The Prostate cancer Research International: Active Surveillance study.
Bangma CH, Bul M, Roobol M.
Curr Opin Urol. 2012 May;22(3):216-21. doi:
10.1097/MOU.0b013e328351dcc7. Review.
PMID:22453333

Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ.
Eur Urol. 2013 Apr;63(4):597-603. doi:
10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12. PMID:23159452

A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ; PRIAS study group..
Eur Urol. 2016 Dec;70(6):954-960. doi:
10.1016/j.eururo.2016.06.007. Epub 2016 Jun 19. PMID:27329565

Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.
Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A.
BJU Int. 2016 Sep;118(3):366-71. doi: 10.1111/bju.13410. Epub 2016 Feb 12.
PMID:26765682

Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP, Alberts AR, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Bangma CH, Roobol MJ; PRIAS study group..
Eur Urol. 2015 Nov;68(5):814-21. doi: 10.1016/j.eururo.2015.06.012. Epub 2015 Jun 29.
PMID:26138043

- Brief summaryThe incidence of prostate cancer has been rising over the last two decades, while the absolute mortality has remained stable. The proportion of men dying WITH prostate cancer instead of FROM prostate cancer has therefore increased. A so called active surveillance strategy of selecting prostate tumors with a favorable prognosis, withholding radical treatment but instead monitoring the tumor with the option of curative treatment at the moment of progression, is indicated in a large proportion of the newly diagnosed prostate cancer. Our international, protocol based, observational study aims to prospectively collect evidence for this stratregy, by applying a strcit protocl of inclusion and followcriteria.
- Main changes (audit trail) 29-apr-2017: -EB


INCLUSION CRITERIA NEW:
1) Histologically proven adenocarcinoma of the prostate.
2) Men should be fit for curative treatment.
3) PSA-level at diagnosis ≤ 10 ng/mL.
4) PSA density (PSA D) less than 0.2.
5) Clinical stage T1C or T2.
6) Gleason score 3+3=6.
7) One or 2 biopsy cores invaded with prostate cancer:
a.
If an MRI, including targeted biopsies on positive lesions, is done at inclusion, there is no limit in the number of positive cores (that is, more than two, and no limit in the % of cancer present in the cores).
b.
If saturation biopsies (either transperineal or transrectal) are done 15% of the cores can be positive with a maximum of 4. (i.e. <20 cores 2 cores can be positive (standard), 20-26 cores 3 cores can be positive, >26 cores 4 cores can be positive) (all other inclusion criteria still apply).
8) Participants must be willing to attend the follow-up visits.
Note: Patients with biopsy Gleason score 3+4 can be followed outside the actual PRIAS protocol.
The patient should be at least 70 years old and should have evidence of limited disease (maximum 10% tumor involvement per biopsy core, maximum 2 cores positive).
Risk reclassification is defined as any upgrading in Gleason score and/or more than 2 positive cores at repeat biopsy.

EXCLUSION CRITERIA NEW:
1) Men who can not or do not want to be radiated or operated.
2) A former therapy for prostate cancer.
- RECORD11-mrt-2009 - 29-apr-2017


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl